Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa.

Bianconi I, Alcalá-Franco B, Scarselli M, Dalsass M, Buccato S, Colaprico A, Marchi S, Masignani V, Bragonzi A.

Front Immunol. 2019 Jan 9;9:3021. doi: 10.3389/fimmu.2018.03021. eCollection 2018.

2.

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.

Maruggi G, Chiarot E, Giovani C, Buccato S, Bonacci S, Frigimelica E, Margarit I, Geall A, Bensi G, Maione D.

Vaccine. 2017 Jan 5;35(2):361-368. doi: 10.1016/j.vaccine.2016.11.040. Epub 2016 Dec 7.

3.

Successful completion of a semi-automated enzyme-free cloning method.

Bonacci S, Buccato S, Maione D, Petracca R.

J Struct Funct Genomics. 2016 Sep;17(2-3):57-66. doi: 10.1007/s10969-016-9207-z. Epub 2016 Aug 9.

PMID:
27507291
4.

The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways.

Pietrocola G, Rindi S, Rosini R, Buccato S, Speziale P, Margarit I.

J Immunol. 2016 Jan 1;196(1):385-94. doi: 10.4049/jimmunol.1501954. Epub 2015 Nov 25.

5.

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gregorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S.

J Virol. 2015 Oct 14;90(1):332-44. doi: 10.1128/JVI.01786-15. Print 2016 Jan 1.

6.

Identification of a Monoclonal Antibody Against Pneumococcal Pilus 1 Ancillary Protein Impairing Bacterial Adhesion to Human Epithelial Cells.

Amerighi F, Valeri M, Donnarumma D, Maccari S, Moschioni M, Taddei A, Lapazio L, Pansegrau W, Buccato S, De Angelis G, Ruggiero P, Masignani V, Soriani M, Pezzicoli A.

J Infect Dis. 2016 Feb 15;213(4):516-22. doi: 10.1093/infdis/jiv461. Epub 2015 Sep 23.

PMID:
26401026
7.

SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains.

Nesta B, Valeri M, Spagnuolo A, Rosini R, Mora M, Donato P, Alteri CJ, Del Vecchio M, Buccato S, Pezzicoli A, Bertoldi I, Buzzigoli L, Tuscano G, Falduto M, Rippa V, Ashhab Y, Bensi G, Fontana MR, Seib KL, Mobley HL, Pizza M, Soriani M, Serino L.

PLoS Pathog. 2014 May 8;10(5):e1004124. doi: 10.1371/journal.ppat.1004124. eCollection 2014 May. Erratum in: PLoS Pathog. 2015 Mar;11(3):e1004773.

8.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

9.

The ancillary protein 1 of Streptococcus pyogenes FCT-1 pili mediates cell adhesion and biofilm formation through heterophilic as well as homophilic interactions.

Becherelli M, Manetti AG, Buccato S, Viciani E, Ciucchi L, Mollica G, Grandi G, Margarit I.

Mol Microbiol. 2012 Mar;83(5):1035-47. doi: 10.1111/j.1365-2958.2012.07987.x. Epub 2012 Feb 10.

10.

Environmental acidification drives S. pyogenes pilus expression and microcolony formation on epithelial cells in a FCT-dependent manner.

Manetti AG, Köller T, Becherelli M, Buccato S, Kreikemeyer B, Podbielski A, Grandi G, Margarit I.

PLoS One. 2010 Nov 5;5(11):e13864. doi: 10.1371/journal.pone.0013864.

11.

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm.

Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, Buttazzoni E, Rosini R, Runci Y, Mora M, Buccato S, Pagani M, Tresoldi E, Berardi A, Creti R, Baker CJ, Telford JL, Grandi G.

J Infect Dis. 2009 Jan 1;199(1):108-15. doi: 10.1086/595564.

PMID:
19086816
12.

Scavenger receptor gp340 aggregates group A streptococci by binding pili.

Edwards AM, Manetti AG, Falugi F, Zingaretti C, Capo S, Buccato S, Bensi G, Telford JL, Margarit I, Grandi G.

Mol Microbiol. 2008 Jun;68(6):1378-94. doi: 10.1111/j.1365-2958.2008.06220.x. Epub 2008 Apr 29.

13.

Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease.

Buccato S, Maione D, Rinaudo CD, Volpini G, Taddei AR, Rosini R, Telford JL, Grandi G, Margarit I.

J Infect Dis. 2006 Aug 1;194(3):331-40. Epub 2006 Jun 30.

PMID:
16826481
14.

Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae.

Rosini R, Rinaudo CD, Soriani M, Lauer P, Mora M, Maione D, Taddei A, Santi I, Ghezzo C, Brettoni C, Buccato S, Margarit I, Grandi G, Telford JL.

Mol Microbiol. 2006 Jul;61(1):126-41.

15.

Identification of a universal Group B streptococcus vaccine by multiple genome screen.

Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, Tettelin H, Brettoni C, Iacobini ET, Rosini R, D'Agostino N, Miorin L, Buccato S, Mariani M, Galli G, Nogarotto R, Nardi-Dei V, Vegni F, Fraser C, Mancuso G, Teti G, Madoff LC, Paoletti LC, Rappuoli R, Kasper DL, Telford JL, Grandi G.

Science. 2005 Jul 1;309(5731):148-50. Erratum in: Science. 2013 Jan 11;339(6116):141. Nardi Dei, Vincenzo [corrected to Nardi-Dei, Vincenzo].

Supplemental Content

Loading ...
Support Center